Physician profile
Julio E Navarro
NPI 1689684581
$13,081.01
in general payments reported to CMS, 2019-2025
54 companies · $2,290 in 2025
The $2,290 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $1,203 · 2021: $2,356 · 2022: $2,371 · 2023: $2,187 · 2024: $2,441 · 2025: $2,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,829 · Travel and Lodging: $90.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,829.03 |
| Travel and Lodging | $90.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,898.90 | 2019-2025 | |
| Lilly USA, LLC | $1,674.66 | 2019-2025 | Mounjaro, Emgality, Zepbound |
| Novo Nordisk INC | $987.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $845.38 | 2020-2025 | |
| Glaxosmithkline, LLC. | $752.10 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $741.98 | 2020-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $604.16 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $550.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Teva Pharmaceuticals USA, INC. | $486.77 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbott Laboratories | $476.40 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $375.00 | 2020-2025 | Verquvo, Belsomra, Steglatro |
| W. L. Gore & Associates, INC. | $321.63 | 2025 | Gore Tag Conformable Thoracic Endoprosthesis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $321.01 | 2019-2024 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $313.35 | 2020-2023 | Livalo, Seglentis |
| Biocryst US Sales Co., LLC | $303.16 | 2024-2025 | Orladeyo |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Navarro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.